Inhibikase Therapeutics (IKT) Debt to Equity (2020 - 2025)
Inhibikase Therapeutics (IKT) has disclosed Debt to Equity for 6 consecutive years, with $0.0 as the latest value for Q2 2025.
- On a quarterly basis, Debt to Equity fell 98.41% to $0.0 in Q2 2025 year-over-year; TTM through Jun 2025 was $0.0, a 98.41% decrease, with the full-year FY2024 number at $0.0, down 91.48% from a year prior.
- Debt to Equity was $0.0 for Q2 2025 at Inhibikase Therapeutics, down from $0.0 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $0.03 in Q1 2021 to a low of -$0.27 in Q3 2024.
- A 5-year average of -$0.01 and a median of $0.01 in 2023 define the central range for Debt to Equity.
- Biggest YoY gain for Debt to Equity was 292.9% in 2024; the steepest drop was 2857.86% in 2024.
- Inhibikase Therapeutics' Debt to Equity stood at $0.01 in 2021, then soared by 31.06% to $0.01 in 2022, then soared by 97.21% to $0.01 in 2023, then crashed by 91.48% to $0.0 in 2024, then plummeted by 59.31% to $0.0 in 2025.
- Per Business Quant, the three most recent readings for IKT's Debt to Equity are $0.0 (Q2 2025), $0.0 (Q1 2025), and $0.0 (Q4 2024).